Welcome to our dedicated page for ContraFect Corporation news (Ticker: CFRX), a resource for investors and traders seeking the latest updates and insights on ContraFect Corporation stock.
ContraFect Corporation (CFRX) maintains this comprehensive news hub for stakeholders tracking advancements in antimicrobial therapies. Our curated collection delivers essential updates on the biotechnology leader’s progress against drug-resistant infections through its pioneering lysin and monoclonal antibody platforms.
Access timely reports on clinical trial developments, regulatory milestones, and strategic collaborations shaping the future of hospital infection treatment. The resource serves investors and healthcare professionals alike with verified information about therapeutic candidates in development and their potential market impact.
Key updates include progress reports on antibacterial agents targeting multidrug-resistant organisms, financial disclosures demonstrating R&D commitment, and partnership announcements with research institutions. All content undergoes rigorous verification to ensure compliance with financial reporting standards.
Bookmark this page for streamlined monitoring of ContraFect’s scientific breakthroughs and corporate developments. For real-time alerts, consult the company’s official investor relations channels alongside this resource.
ContraFect Corporation (CFRX) reported Q2 2022 results, highlighting a net loss of $18.1 million, equating to a loss of $0.46 per share, up from a loss of $5.4 million, or $0.14 per share, a year earlier. R&D expenses soared to $16.8 million due to increased spending on exebacase and CF-370. Following a Phase 3 trial setback for exebacase, the company aims to initiate new studies for intra-articular exebacase for prosthetic joint infections. They expect to file for CF-370 clinical trials soon. Cash and equivalents stood at $27.3 million as of June 30, 2022.
ContraFect Corporation (Nasdaq: CFRX) announced a manuscript publication in the Journal of Bone and Joint Infection on the efficacy of exebacase (CF-296 lysin) in treating methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis in a preclinical rabbit model. Findings indicate significant reductions in MRSA counts, even with exebacase administered alone. The company is evaluating exebacase's potential for clinical studies in prosthetic joint infections and is also considering further development of CF-296.
ContraFect Corporation (Nasdaq: CFRX) announced the termination of the DISRUPT trial, evaluating exebacase for treating antibiotic-resistant infections. The Data Safety Monitoring Board (DSMB) found the study's conditional power insufficient, suggesting a halt due to low clinical response rates among 84 patients analyzed. The primary endpoint, clinical response at Day 14, did not meet expectations. The company will review further data and communicate with trial investigators about the enrollment cessation and next steps for exebacase, which previously received FDA Breakthrough Therapy designation.
ContraFect Corporation (Nasdaq: CFRX) presented data at the ASM Microbe Conference that its lead product candidate, exebacase, shows effectiveness against methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections. Recognized as a Breakthrough Therapy by the FDA, exebacase demonstrated significant bacterial reduction in a rabbit model of implant-associated osteomyelitis. The data also indicated low propensity for resistance development and suppression of antibiotic resistance. Ongoing Phase 3 trials aim to further validate exebacase's potential as a treatment for MRSA infections.
ContraFect Corporation (Nasdaq: CFRX) announced its selection to present two posters at the ASM Microbe Conference 2022 in Washington, D.C., from June 9-13, 2022. The presentations focus on the company's exebacase, a Breakthrough Therapy candidate for antibiotic-resistant infections. Key findings include exebacase's low propensity for developing resistance and its efficacy in treating MRSA infections, showing a significant clinical responder rate. Exebacase is currently undergoing pivotal Phase 3 clinical trials.
ContraFect Corporation (Nasdaq: CFRX) announced the grant of stock options for 15,000 shares to two new non-executive employees on May 16, 2022. This grant, part of the 2021 Inducement Plan, has a ten-year term and an exercise price of $3.20 per share. The options vest over four years, with 25% vesting after 12 months and the remainder quarterly. ContraFect specializes in developing direct lytic agents to combat antibiotic-resistant infections, notably with their lead candidate, exebacase, currently in a pivotal Phase 3 study for treating MRSA bloodstream infections.
ContraFect Corporation (CFRX) announced key developments in its Phase 3 DISRUPT study, achieving the enrollment of over 60% of MRSA patients needed for an interim futility analysis, expected in early July 2022. The Q1 2022 results reflected a net loss of $20.2 million, or $(0.51) per share, up from a loss of $5.2 million or $(0.18) per share in Q1 2021. Research and development expenses rose to $12.7 million, driven by clinical activities and manufacturing costs related to exebacase. As of March 31, 2022, the company had $42.3 million in cash and securities.
ContraFect Corporation (CFRX) announced promising results for its investigational drug, CF-370, presented at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). The drug showed significant efficacy in a rabbit pneumonia model infected with an extensively drug-resistant strain of Pseudomonas aeruginosa. CF-370 not only reduced bacterial counts significantly but also demonstrated the ability to suppress antimicrobial resistance against standard antibiotics. These findings suggest CF-370's potential for treating severe infections where current antibiotics fail.
ContraFect Corporation (Nasdaq: CFRX) announces its selection for an oral presentation and six poster presentations at the 32nd ECCMID Annual Meeting from April 23-26, 2022, in Lisbon, Portugal. The presentation will highlight findings from the pivotal Phase 3 study of exebacase, a product candidate designed to combat antibiotic-resistant infections. This includes the efficacy of CF-370 in treating extensively drug-resistant Pseudomonas aeruginosa and its interaction with conventional antibiotics. The meetings aim to bolster the company's profile in the biotechnology sector.
ContraFect Corporation (CFRX) reported its fourth quarter and full-year 2021 results, indicating progress in the Phase 3 DISRUPT study of exebacase, expected to conduct an interim futility analysis in H1 2022. The company received a contract from the Cystic Fibrosis Foundation to study exebacase in treating MRSA lung infections. Q4 2021 net loss was $4.4 million, improving from the previous year's $6.4 million loss. Total cash and equivalents stood at $54.3 million as of December 31, 2021, with R&D expenses rising to $11 million due to increased clinical trial activities.
